Sleep Disorders Treatment Drugs Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Japan, China, India, Australia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Sleep Disorders Treatment Drugs Market size is projected to experience significant growth from 2019 to 2025.
 

Sleep disorders treatment drugs are compounds that are prescribed by the doctors and physicians to the people suffering from intrinsic as well as extrinsic sleeping disorders. Sleep drugs are particularly categorized into several classes including sedative-hypnotics, benzodiazepines, dual orexin receptor antagonists, melatonin receptor agonists, antidepressants and others. These drugs have reduced the mortality rates in people suffering from insomnia due to strokes and other chronic illness.
 

Get more details on this report - Request Free Sample PDF
 

Increasing prevalence of sleeping disorders is expected to spur the demand for sleep disorder treatment drugs market. According to a study, over 50 million Americans suffer from some kind of sleep disorder. Around 35% of the American adults experience short-term insomnia symptoms. Similar is the condition in developing and underdeveloped economies. For instance, more than 15% of the total population in China suffers from insomnia. Moreover, industry players invest in research and development activities to develop novel drugs that help in over coming the sleeping disorders. Thus, availability of sleep inducing drugs having high efficacy for treating sleep disorder will positively impact the industry growth.
 

Growing interest of industry players for developing superior quality sleep inducing drugs will elevate the sleep disorders treatment drugs market growth. Key players such as Merck and others have focused on launching new formulations that will enhance the sleep activity in individuals suffering from chronic sleeping disorders such as insomnia sleep apnea and narcolepsy. For instance, Merck introduced new drug for treating insomnia that gained momentum and was highly prescribed by the healthcare professionals for treating insomnia. Therefore, introduction of such new drugs for treating sleeping disorders will foster the industry growth. However, stringent regulatory landscape may hamper the demand for sleep drugs thereby, restraining the market growth. This factor would have a mid-term impact and would vanish gradually with improvements in the regulatory scenario.
 

Antidepressants segment of the sleeping disorders treatment drugs market held considerable revenue share in 2018 and is projected to foresee exceptional growth during the analysis period. Antidepressants are a class of drugs that helps in management of sleeping disorders caused due to depression. These drugs essentially rectifies chemical imbalances of neurotransmitters in the brain. Moreover, antidepressants improve mood that helps individual to sleep better. Aforementioned factors will escalate the segmental growth in the near future.
 

Extrinsic sleep disorders segment will witness substantial growth in the forthcoming years. Causes of extrinsic sleep disorders include poor sleep hygiene, food allergies and environmental factors. Globally, millions of people suffer from extrinsic sleep disorders due to external disturbances. Environmental sleeping disorders are major contributors for the elevated demand for sleep inducing pills.  People suffering from environmental disorders not only have preference towards sleep tracking devices but also have high reliance on the sleep drugs that should propel the segmental growth.
 

North America sleep disorders treatment drugs market accounted for prominent revenue share in 2018. Considerable regional growth can be attributed to the favorable demographic trends. Rising geriatric population suffering from sleeping disorders such as narcolepsy and insomnia increases the demand for sleep drugs. Furthermore, improving regulatory scenario proves beneficial for the industry growth. Regulatory authorities frame laws and guidelines that assure availability of superior quality drugs that do not cause any adverse events. Above mentioned factors are expected to boost the industry growth in the coming years.
 

Alexza Pharmaceuticals, Astellas Pharma, Merck, Athenex, Eisai, Evotec, Ferring International Center, Galenica, Heptares Therapeutics are some of the major market players involved in the global sleep disorders treatment drugs market. Key players are implementing strategic initiatives such as mergers and acquisitions as well as product launches for maintaining their market position. For instance, Merck developed insomnia drug Belsomra that wad highly effective in the treatment of insomnia. Thus, launch of new products will not only strengthen company’s product portfolio but will also, boost company’s growth.
 

Sleep Disorders Treatment Drugs Market, By Drug Class, 2014-2025 (USD Million)

• Sedative-hypnotics
• Benzodiazepines
• Dual orexin receptor antagonists
• Melatonin receptor agonists
• Antidepressants
• Others

Sleep Disorders Treatment Drugs Market, By Application, 2014-2025 (USD Million)

• Intrinsic sleep disorders
  • Psychophysiological insomnia
  • Narcolepsy
  • Restless legs syndrome
  • Obstructive sleep apnea syndrome
  • Others
• Extrinsic sleep disorders
  • Environmental sleep disorder
  • Food allergy insomnia
  • Toxin-induced sleep disorder
  • Others
• Others

Sleep Disorders Treatment Drugs Market, By Distribution Channel, 2014-2025 (USD Million)

• Retail pharmacies
• Online platforms
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Mexico
  • Brazil
• Middle East and Africa
  • South Africa
  • Saudi Arabia

Company Profiles:

• Alexza Pharmaceuticals Inc
• Astellas Pharma Inc
• Athenex Inc
• Eisai Co Ltd
• Evotec AG
• Ferring International Center SA
• Galenica Ltd
• Heptares Therapeutics Ltd

What Information does this report contain?